Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis
Braun A, Liu L, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Attention Deficit Hyperactivity Disorder among Youth at Clinical High Risk of Psychosis. Schizophrenia Bulletin Open 2024, sgae028. DOI: 10.1093/schizbullopen/sgae028.Peer-Reviewed Original ResearchClinical high riskCo-morbid ADHDClinical high risk of psychosisPredictors of transition to psychosisNorth American Prodrome Longitudinal StudySubstance useClinical high-risk individualsClinical high-risk participantsClinical high-risk youthHigh risk of psychosisAttention deficit hyperactivity disorderNegative psychotic symptomsTransition to psychosisCo-morbid disordersNon-ADHD groupRisk of psychosisDeficit hyperactivity disorderCo-morbidityIncreased substance useAssociated with numerous adverse outcomesPsychotic symptomsNumerous adverse outcomesPremorbid functioningSocial cognitionADHD groupSex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Chintoh A, Liu L, Braun A, Akseer S, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, McGlashan T, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research 2024, 271: 153-160. PMID: 39029145, DOI: 10.1016/j.schres.2024.07.030.Peer-Reviewed Original ResearchClinical high riskClinical high-risk individualsSex differencesNegative symptomsTransition to psychosisInvestigate sex differencesNo sex differencesSchizophreniform disorderCHR individualsPsychosisSubstance useSchizophreniaSymptomsHigh riskIndividualsSchizophreniformAnxietyClinical presentationSexDepressionDisordersBaselineDifferencesMaleYouthAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsProteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study
Byrne J, Healy C, Föcking M, Susai S, Mongan D, Wynne K, Kodosaki E, Heurich M, de Haan L, Hickie I, Smesny S, Thompson A, Markulev C, Young A, Schäfer M, Riecher-Rössler A, Mossaheb N, Berger G, Schlögelhofer M, Nordentoft M, Chen E, Verma S, Nieman D, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, McGorry P, Amminger P, Cagney G, Nelson B, Jeffries C, Perkins D, Cotter D. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin 2024, 50: 579-588. PMID: 38243809, PMCID: PMC11059811, DOI: 10.1093/schbul/sbad184.Peer-Reviewed Original ResearchClinical high riskTransition to psychosisAssociated with transition to psychosisClinical high-risk cohortNorth American Prodrome Longitudinal Study 2Predicting transition to psychosisDevelopment of psychosisLongitudinal Study 2Group levelPlasma proteomics dataCHR participantsPsychosis riskPrediction of transitionPsychosisStudy 2High riskLongitudinal associationsStudy follow-up periodRandomized controlled trialsLogistic regression modelsMultiple comparisonsPrimary outcomeProteomic biomarkersControlled trialsGlycoprotein 1Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales